NDAORALTABLETPriority Review
Approved
Jul 2006
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
15
Mechanism of Action
fixed-dose combination of antiviral drugs efavirenz, emtricitabine and tenofovir disoproxil fumarate. [See ].
Clinical Trials (5)
B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults
Started Oct 2018
28 enrolled
HIV-1-infection
Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
Started Mar 2016
86 enrolled
HIV-1Central Nervous System
SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
Started Nov 2015
40 enrolled
HIV
Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla
Started Sep 2015
30 enrolled
HIV-1
Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects
Started Jul 2015
74 enrolled
Impaired CognitionDepression/AnxietyPoor Quality Sleep+2 more
Loss of Exclusivity
LOE Date
Apr 28, 2029
38 months away
Patent Expiry
Apr 28, 2029